Tuesday

16th Oct 2018

EU drugs regulator accused of being too cozy with Big Pharma

  • The parliament has slammed the EU drugs regulator for cozying up to Big Pharma (Photo: www.freeimages.co.uk)

The European Parliament has refused to sign off on the accounts of the EU agency responsible for making sure all medicines in Europe are safe and effective for its citizens to use, accusing the body of being too close to Big Pharma.

The European Medicines Agency's reputation was further bludgeoned on Tuesday when the parliament ordered a special investigation of the regulator over its funding sources, which overwhelmingly come from the pharmaceutical industry and its hiring practices.

Read and decide

Join EUobserver today

Support quality EU news

Get instant access to all articles — and 18 year's of archives. 30 days free trial.

... or join as a group

Completing the bad news for the agency whose claims of objectivity now lie in tatters were accusations from doctors from the Nordic Cochrane Centre, an independent Denmark-based network that publishes systematic reviews of drug efficacy, that the EMA withholds drug trial evidence due for fear of hurting the profits of drug companies.

On Tuesday, a crushing majority of MEPs in a 637-to-four vote refused to sign off on the accounts of the EMA.

There is "no proper guarantee of the independence of experts hired to carry out scientific evaluations of human medicines and some experts had conflicting interests," according to a statement issued by the chamber that described its concerns about the agency as "grave".

A report backed by the deputies that deploys the term "unacceptable" no fewer than five times and describes its concerns as "grave", describes how at the agency, "there is no guarantee that the evaluation of human medicines is performed by independent experts."

According to the MEPs, the alarm is being raised as a result of both hiring practices that do not pay attention to potential staff and expert conflicts of interest and the source of the bulk of the agency's funding, the pharmaceutical industry itself.

The report goes on to warn of "potential risks to the independence of experts/staff involved in the evaluation of medicinal products, which could have not only detrimental consequences to the agency's reputation should the evaluation of products be formally questioned, but also might have negative effects on public health."

The report mentions the case of the EMA's former executive director, Thomas Lonngren, who in December last year, resigned his post announcing that the next month, he was to take up another job for a private consultancy advising the pharmaceutical industry on the development of new medicines and reducing how long it takes to bring a product to market.

The MEPs' report "stresses that this move casts some doubt on the actual independence of the agency."

Within days of Lonngren's announcement, the EMA management board gave this case of ‘revolving doors' a green light, declaring that there was no conflict of interest and wishing him "all success in your future endeavours".

The parliament argued that the board was within its rights to forbid this type of employment, but did not and has demanded that the EMA deliver a list of all comparable cases that have occurred since the creation of the agency and "explain thoroughly the management board's decision in each case."

The case of the slimming pill

The MEPs in particular highlighted the case of the "very late withdrawal from the market" of a so-called slimming pill, benflourex, which was sold under the brand name ‘Mediator', and also demanded "a full and extensive report" from the agency explaining why it took 10 years from the date when the first warning of possible dangerous side effects of this drug was communicated to the agency, before the final decision was taken to withdraw the drug in 2009.

The EMA may yet get into more hot water over this case, as the chamber has asked the agency to detail how any experts and staff involved with the Mediator case were screened for their independence and verified that there was no conflict of interest.

The same day as the vote, the British Medical Journal published an article by two Danish doctors, Peter Gøtzsche and Anders Jørgensen, of the Nordic Cochrane Centre, detailing their struggle to get the EMA to release the results of clinical trials performed on another pair of slimming pills the agency had given the all-clear to.

The one drug, rimonabant from Sanofi-Aventis, traded under brand names such as Slimona and Monaslim until it was taken off the market last year as a result of side effects, notably severe depression and suicidal thoughts. The second, orlistat, is marketed as a prescription under the name Xenical, from Roche, or over the counter as Alli, from GlaxoSmithKline. Public Citizen, a consumer advocacy group has criticised the weight-loss drug's approval questioning its efficacy and raising concerns about side-effects including precancerous lesions of the colon.

"The effect on weight loss in the published trials is small, and the harms are substantial," the doctors wrote in their article. "People have died from cardiac and pulmonary complications or have experienced psychiatric disturbances, including suicidal events, and most of the drugs have been deregistered for safety reasons."

But the EMA refused to release the clinical trial data for three years, arguing that to do so "would undermine commercial interests."

Commercial interests versus patient welfare

Only after a ruling in June 2010 by the European ombudsman ordering the agency to cough up the information, accusing it of maladministration, did the EMA acquiesce, and it still took the body until February this year to do so.

"The EMA put protecting the profits of the drug companies ahead of protecting the lives and welfare of patients," said the doctors.

The agency's clinical trials database, Eudract, is kept hived off from public scrutiny, despite regular promises to make the information available.

The parliament on Tuesday formally called for a special investigation of conflict of interest at the agency. The chamber at the same time asked for a similar investigation of the European Police College and refused to sign off the accounts for the EU Council of Ministers, although it approved most of the EU's 2009 spending.

After the vote, Green MEP and deputy chair of the parliament's budgetary control committee, Bart Staes, said simply: "The EMA is a mess."

Exclusive

Commission tried to hide details of 'WiFi4EU' glitch

The commission heavily redacted documents released to EUobserver because they were reportedly 'out of scope'. Transparency campaigner Helen Darbishire says however the information was "clearly directly relevant to the request".

Brexit standoff continues before EU summit

As negotiations halt ahead of the EU summit later this week, British prime minister Theresa May told her parliament the Irish border issue should not derail a Brexit deal.

Stakeholder

ASEM: Global Partners for Global Challenges

As anti-globalisation and protectionist sentiments threaten to come back, it is more important than ever for ASEM members to come together, think in the long term, and take coordinated actions to resist unilateralism and uphold multilateralism.

Interview

How Juncker's 'do less' group concluded EU should not do less

EUobserver followed Karl-Heinz Lambertz, the president of the Committee of Regions over nine months - and six interviews - as he worked on one of Jean-Claude Juncker's pet projects: one of the five so-called 'future of Europe' scenarios.

Brexit standoff continues before EU summit

As negotiations halt ahead of the EU summit later this week, British prime minister Theresa May told her parliament the Irish border issue should not derail a Brexit deal.

Magazine

Tug of war between 'top-down' and 'bottom-up' cohesion money

The European Commission has promised greater flexibility for local authorities when it comes to delivering on-the-ground results - but it has also tied cohesion policy to the European Semester, a tool used to coordinate macroeconomic policies.

Stakeholders' Highlights

  1. International Partnership for Human RightsOpen letter to Emmanuel Macron ahead of Uzbek president's visit
  2. International Partnership for Human RightsRaising key human rights concerns during visit of Turkmenistan's foreign minister
  3. NORDIC COUNCIL OF MINISTERSState of the Nordic Region presented in Brussels
  4. NORDIC COUNCIL OF MINISTERSThe vital bioeconomy. New issue of “Sustainable Growth the Nordic Way” out now
  5. NORDIC COUNCIL OF MINISTERSThe Nordic gender effect goes international
  6. NORDIC COUNCIL OF MINISTERSPaula Lehtomaki from Finland elected as the Council's first female Secretary General
  7. NORDIC COUNCIL OF MINISTERSNordic design sets the stage at COP24, running a competition for sustainable chairs.
  8. Counter BalanceIn Kenya, a motorway funded by the European Investment Bank runs over roadside dwellers
  9. ACCACompany Law Package: Making the Best of Digital and Cross Border Mobility,
  10. International Partnership for Human RightsCivil Society Worried About Shortcomings in EU-Kyrgyzstan Human Rights Dialogue
  11. UNESDAThe European Soft Drinks Industry Supports over 1.7 Million Jobs
  12. Mission of China to the EUJointly Building Belt and Road Initiative Leads to a Better Future for All

Latest News

  1. EU ministers struggle to deal with Poland and Hungary
  2. Commission tried to hide details of 'WiFi4EU' glitch
  3. Brexit standoff continues before EU summit
  4. ASEM: Global Partners for Global Challenges
  5. How Juncker's 'do less' group concluded EU should not do less
  6. Cyprus and Russia: Association of Cyprus Banks responds
  7. Orthodox church split just tip of Putin's crumbling 'soft power' in Ukraine
  8. Daily reality in Western Sahara - and how EU can protect it

Stakeholders' Highlights

  1. International Partnership for Human RightsCivil society asks PACE to appoint Rapporteur to probe issue of political prisoners in Azerbaijan
  2. ACCASocial Mobility – How Can We Increase Opportunities Through Training and Education?
  3. Nordic Council of MinistersEnergy Solutions for a Greener Tomorrow
  4. UNICEFWhat Kind of Europe Do Children Want? Unicef & Eurochild Launch Survey on the Europe Kids Want
  5. Nordic Council of MinistersNordic Countries Take a Stand for Climate-Smart Energy Solutions
  6. Mission of China to the EUChina: Work Together for a Better Globalisation
  7. Nordic Council of MinistersNordics Could Be First Carbon-Negative Region in World
  8. European Federation of Allergy and AirwaysLife Is Possible for Patients with Severe Asthma
  9. PKEE - Polish Energy AssociationCommon-Sense Approach Needed for EU Energy Reform
  10. Nordic Council of MinistersNordic Region to Lead in Developing and Rolling Out 5G Network
  11. Mission of China to the EUChina-EU Economic and Trade Relations Enjoy a Bright Future
  12. ACCAEmpowering Businesses to Engage with Sustainable Finance and the SDGs

Stakeholders' Highlights

  1. Nordic Council of MinistersCooperation in Nordic Electricity Market Considered World Class Model
  2. FIFAGreen Stadiums at the 2018 Fifa World Cup
  3. Mission of China to the EUChina and EU Work Together to Promote Sustainable Development
  4. Counter BalanceEuropean Ombudsman Requests More Lending Transparency from European Investment Bank
  5. FIFARecycling at the FIFA World Cup in Russia
  6. Nordic Council of MinistersOECD Report: Gender Equality Boosts GDP Growth in Nordic Region
  7. Centre Maurits Coppieters“Peace and Reconciliation Is a Process That Takes Decades” Dr. Anthony Soares on #Brexit and Northern Ireland
  8. Mission of China to the EUMEPs Positive on China’s New Measures of Opening Up
  9. Macedonian Human Rights MovementOld White Men are Destroying Macedonia by Romanticizing Greece
  10. Counter BalanceControversial EIB-Backed Project Under Fire at European Parliament
  11. Nordic Council of MinistersIncome Inequality Increasing in Nordic Countries
  12. European Jewish CongressEU Leaders to Cease Contact with Mahmoud Abbas Until He Apologizes for Antisemitic Comments

Join EUobserver

Support quality EU news

Join us